WO2024201245 - COMPOSITIONS COMPRISING 5-METHOXY-2-AMINOINDAN FOR TREATMENT OF DEPRESSION
National phase entry:
Publication Number
WO/2024/201245
Publication Date
03.10.2024
International Application No.
PCT/IB2024/052773
International Filing Date
22.03.2024
Title **
[English]
COMPOSITIONS COMPRISING 5-METHOXY-2-AMINOINDAN FOR TREATMENT OF DEPRESSION
[French]
COMPOSITIONS COMPRENANT DU 5-MÉTHOXY-2-AMINOINDANE POUR LE TRAITEMENT DE LA DÉPRESSION
Applicants **
CLEARMIND LABS CORP.
Inventors
ZULOFF-SHANI, Adi
Priority Data
63/492,837
29.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4203 | |
| EPO | Filing, Examination, Granting | 75380 | |
| Japan | Filing, Examination, Granting | 4493 | |
| South Korea | Filing, Examination, Granting | 6431 | |
| USA | Filing, Examination, Granting | 20140 |
Total:
110,647
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to pharmaceutical compositions comprising 5- methoxy-2-aminoindan, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient, and their use in methods of 5 treating depression by administrating said compositions to a subject in need thereof in a therapeutically effective amount.[French]
La présente invention concerne des compositions pharmaceutiques comprenant du 5-méthoxy-2-aminoindane, ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un support et/ou excipient pharmaceutiquement acceptable, et leur utilisation dans des méthodes de traitement de la dépression par administration desdites compositions à un sujet en ayant besoin en une quantité thérapeutiquement efficace.